PharmaBoardroom

Sanofi’s Paul Hudson on Maintaining Innovation Momentum

The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT…

China Still Hesitant to Embrace mRNA COVID Vaccines as Omicron…

Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a…

Moderna: Bullish Bancel “Not Losing Sleep” over COVID-19…

The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the…

The bright future of mRNA technology – InConversation…

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…

Thomas D. Madden – CEO, Acuitas Therapeutics